The simultaneous blockade of PD-1 and VEGF ("cooperativity") by one molecule may produce enhanced antitumor activity with an improved safety profile compared with the co-administration of separate ...

and suggests that PD-1/PD-L1 therapies may have a direct effect on macrophages too. Combinatorial blockade of PD-L1 and CD47 has been shown to enhance antitumor effects in vivo 1, which presents ...

MedServe, in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) and the Africa Research Group for Oncology ...

Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis. Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in ... combinations involving blockade of more than one ...

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...

Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while ...

These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene ...